GlassScriptPhysician profile
Thor T Markwood
NPI 1134212616
$8,199.84
in general payments reported to CMS, 2019-2025
33 companies · $1,235 in 2025
The $1,235 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,552 · 2020: $1,115 · 2021: $718 · 2022: $676 · 2023: $1,081 · 2024: $822 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769 · Travel and Lodging: $338 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.88 |
| Travel and Lodging | $337.72 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,143.07 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Selectsecure |
| Medtronic Vascular, INC. | $1,643.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $623.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $566.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.43 | 2019-2025 | Jardiance |
| Biosense Webster, INC. | $333.01 | 2019-2025 | Carto 3, Qdot Micro Catheter |
| Amgen INC. | $307.99 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $275.31 | 2019-2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $250.26 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $228.30 | 2019-2025 | Wainua |
| Lexicon Pharmaceuticals, INC. | $216.60 | 2023-2024 | Inpefa |
| Pfizer INC. | $177.64 | 2019-2024 | |
| Abiomed | $141.10 | 2020-2024 | Impella |
| Chiesi USA, INC. | $91.94 | 2019-2020 | |
| Novo Nordisk INC | $82.42 | 2023-2024 | Ozempic, Wegovy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $68.27 | 2022-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $66.44 | 2022-2025 | Verquvo |
| Cvrx, INC. | $61.41 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $59.12 | 2019 | |
| Atricure, INC. | $47.71 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $41.60 | 2025 | Onpattro |
| Astellas Pharma US INC | $35.34 | 2019 | |
| Amarin Pharma, INC. | $21.48 | 2019 | |
| Cardiovascular Systems INC. | $20.97 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.28 | 2023 | Uptravi |
| Vifor Pharma, INC. | $16.91 | 2019 | |
| Covidien LP | $16.81 | 2019 | |
| Altathera Pharmaceuticals LLC | $16.42 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.35 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2025 | |
| Daiichi Sankyo INC. | $15.88 | 2025 | Injectafer |
| Esperion Therapeutics, INC. | $14.21 | 2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $13.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thor Markwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.